Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in Graves' Disease
NCT07018323Phase 2Recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 2 trial of IMVT-1402 in Graves' disease, sponsored by Immunovant, Inc.. Started Jun 2025; status: recruiting.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT07018323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018323.